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ABSTRACT 
Background:  Blinding minimizes measurement bias, particularly when the outcome being 
assessed is patient-reported, since psychological measures of well-being and symptoms are 
influenced by expectations of the effectiveness of a treatment, which can come either from 
aspects of the intervention or from physician communication.  Blinding of investigators 
collecting patient reported outcomes may be easy, but in surgery, blinding of the participant is 
impossible without a procedural control.  A sham procedural control allows for participant 
blinding and serves to mimic the psychosocial context a patient will experience, which accounts 
for the placebo effect before analysis. 
Purpose: To investigate the use and reporting of sham procedural controls in cardiac procedural 
randomized controlled trials (RCTs) assessing patient-reported outcomes. 
Data Sources: Cardiac RCTs published in The Lancet and The New England Journal of 
Medicine from 1/2005 to 1/2016. 
Study Selection: RCTs of adults (1) investigating an intervention that involved an invasive 
procedure for treating a cardiac disease, (2) with the potential to use a sham control, and (3) 
reporting patient-reported outcomes.   
Data Extraction: A single reviewer extracted data from the full-text.  
Data Synthesis: Of the 11 studies that could have used a sham procedural control, only 1 used a 
sham control and blinded both participants and research assessors to intervention group 
randomization.  The remaining 10/11 surgery studies that assessed quality of life outcomes did 
not blind patients to their intervention group, leading to a high risk of measurement bias.  
Limitations: Identification of published cardiac surgery RCTs was limited to two journals.  A 
single reviewer completed all abstract reviews, full-text reviews, and data extraction.   
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Conclusions: Surgical research investigating the effect of a procedural intervention on patient-
reported outcomes often do not use the ideal of a sham procedural control and often do not 
provide sufficient reporting about methods of collecting the patient reported outcome or the 
blinding status of the research assessor.  The challenges of incorporating sham procedural 
controls in surgical studies include obtaining IRB approval, risk of low study enrollment, 
increased study costs, or fear of unavoidable ethical concerns.  Nevertheless, these problems in 
weighing the benefits and risk of a study are not unique to surgical study design.  More surgical 
studies that evaluate cardiac procedures using patient-reported outcomes should use sham 
controls to improve study result validity.   
Funding: There is no funding or sponsor associated with this study.  
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INTRODUCTION 
 The gold standard of research design is a double-blinded randomized placebo-controlled 
trial.  Although an Institutional Review Board must review all human subjects research proposal, 
the Food and Drug Administration (FDA) regulates the research and grants approval of drugs 
and devices for human use, while the Department of Health and Human Services (DHHS) 
regulates clinical trials of other therapies, such as surgeries.1, 2  For approval of new drugs and 
new devices, placebo-controlled testing is nearly unavoidable and new drugs must undergo a 
four-phase evaluation process while new devices undergo a premarketing approval process.3,4  
Yet, new drugs and new devices can bypass the more stringent approval process by taking a fast-
track evaluation route if the aim is to treat a serious or life-threatening medical condition or if the 
design and function is similar to a prior approved device.4, 5  In contrast, innovations in surgical 
procedures do not require adherence to a predefined developmental pathway or to the gold 
standard of testing, because a randomized placebo-controlled trial in surgery would require a 
sham procedural control—a surgical placebo.   
A placebo is an inert element administered to a control group so that participants in the 
control group have similar expectations about the effectiveness of treatment as those in the 
intervention group.  This psychological expectation is important to equalize between groups, 
because it has the potential to create a placebo effect, which is a non-specific therapeutic effect 
that may be observed on neuroimaging or measurable through patient-reported outcomes.6   
A placebo in a surgical study, also known as a “sham procedure”, entails a skin incision 
and unawareness of the operative process to create the perception of having received a surgery in 
which the therapeutic intervention is not given.  A sham procedural control is unnecessary for 
assessing outcomes not strongly influenced by a placebo effect on psychological state and 
2 
 
 
perception, such as mortality outcomes.  Thus, a sham procedure control is only necessary to 
eliminate measurement bias in studies that assess patient-reported outcomes, because an 
individual’s psychological state influences the patient’s reported outcome.  
This pilot systematic review aims to investigate the use and reporting of sham procedural 
controls in cardiac RCTs with patient-reported outcomes from 1/2005 to 1/2016 in The Lancet 
and The New England Journal of Medicine.   
 
Definition of Placebo and Placebo Effect 
The word placebo first came into vernacular use in the 1300s, when St. Jerome 
erroneously translated Psalm 116:9 from Hebrew into Latin.7, 8  The Hebrew of “I will walk 
before the Lord in the land of the living” turned into the Latin “I shall please (Placebo) the Lord 
in the land of the living.”8  Mourners hoping to gain a reward from the family of the deceased or 
hired as stand-ins for members of the family sung the verse during funeral services, thus linking 
the word placebo with sycophancy and substitution.7, 8 
It was not until 1785 that the word placebo gained a medical definition in A New Medical 
Dictionary as “a commonplace method or medicine”.7  Over time, placebos connoted an inert 
medicine that could not harm but could at least please or comfort a patient.7, 9  Treatments such 
as bread pills, drops of colored water, and subcutaneous water were widespread into the 1890s.7  
In 1906, the passage of the first Pure Food and Drug Act led to a decrease in placebo remedies, 
but eventually, placebos reemerged as a presence in clinical trials.9   
One of the earliest documented use of placebos in cardiac clinical research was by Gold 
and colleagues.  Given conflicting research results on xanthine as a treatment for angina, they 
conducted a crossover study comparing the effect of a xanthine tablet to a placebo lactose table 
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for treating angina.  The results showed that the proportion of people with worsened, stable, or 
improved perceived pain after using xanthine was similar to those using the lactose placebo, 
which concluded that xanthine was an ineffective treatment for angina.  From these results, the 
researchers hypothesize that the supposedly inert lactose tablet may have led to a perceived 
improvement in chest pain through “confidence aroused in a treatment”, “encouragement 
afforded by a new procedure”, and “a change in medical advisor.”10 
Our twenty-first century understanding defines Gold and colleagues’ observation as the 
placebo effect.  Giving a placebo to participants in the control group creates a psychosocial 
context that attempts to mimic the psychosocial context experienced by participant receiving the 
study intervention.  The psychosocial context is a combination of variables that include both 
individual and clinician characteristics and interaction among the patient, clinician, and the 
treatment environment.  The hypothesis made by Gold and colleagues are associated with 
“expectancy” or the “patient-practitioner relationship” components of the placebo effect.6  
Kaptchuk et al found that various component parts combine in a graded dose escalation to create 
a placebo effect, of which the patient-practitioner relationship is the most substantial 
component.11  Furthermore, the mode of intervention delivery influences a patient’s expectations 
and makes a graded dose contribution to the placebo effect.6  For example, in a systematic 
review of placebo effectiveness as migraine prophylaxis, more invasive treatment methods were 
associated with a greater reduction in migraine frequency.  The proportion of responders was 
greatest for sham surgery (58%), followed by sham acupuncture (38%), and then oral 
pharmacological placebo (22%).12  An implication of that review is double blinding of both 
participants and investigators to a participant’s assigned treatment is imperative for equalizing 
expectancy and the patient-practitioner relationship experience across study groups.  Lastly, the 
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psychosocial context that creates a placebo effect may work by activating various neurologic 
pathways that produce the experience of a therapeutic effect.  Neuroimaging revealed release of 
endogenous opioids and dopamine, and this release can be to a specific body region.6  Perhaps, 
this explains the targeted relief of chest pain in the Gold et al study.  
 
Importance of Sham Placebos in Surgery Research 
In 1959, Cobb et al published a surgical study on internal mammary artery ligation, a 
popular procedure for treating angina at the time.  Since decreased blood flow to the myocardium 
causes chest pain, physicians thought tying sutures around two of the mammary arteries would 
redirect the collateral blood flow into the coronary artery.  The study included 17 patients, in 
which 5 of 8 patients who received the ligation procedure and 5 of 9 patients who received a skin 
incision or sham surgery reported “significant subjective improvement.”  This suggested that the 
therapeutic effect was not from redirected blood flow but was a placebo effect.13  One year later, 
Diamond et al published similar findings.14  Thus, physicians stopped giving internal mammary 
ligation procedure to treat angina, but by then, a quarter of a million people had already received 
the ineffective procedure.15  Other surgical studies that may not have used a sham procedural 
control but led to discontinuation of what were once well-established surgical practices include 
radical mastectomy and extracranial to intracranial bypass.16, 17 
Likewise in 2002, when Moseley et al compared the effect of knee arthroscopy with 
debridement and lavage to either arthroscopic lavage alone or sham arthroscopy, the results 
showed similar improvement in symptoms across the three groups.18  These arthroscopy 
procedures costed society over $3 billion dollars annually.15  Other surgical RCTs that stimulated 
controversy about the importance of sham controls were fetal-tissue transplantation in treating 
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Parkinson’s, vertebroplasty for compression fractures, and renal denervation for resistant 
hypertension.19-22      
 
Few Studies on Procedural Innovations 
Although RCTs can improve surgical practice and medicine is moving toward evidence-
based practices, the frequency of surgical RCTs remains low at 9% in 1993 to 8% in 2006.23  
Even in August 2009, when there were 10,974 ongoing RCTs, the majority of trials was testing 
drugs (59%) and a small proportion tested procedure or devices (7% each).24  These few 
published surgical RCTs received criticism for not meeting quality-reporting standards. 
Compared to general medicine RCTs, surgical RCTs received a significantly lower score when 
evaluated by the 2001 Consolidated Standards for Reporting of Trials (CONSORT) guidelines.  
The sample size was small, but for the 8 medical studies analyzed, the interquartile range of the 
CONSORT score was 81-86, whereas the range for the 61 surgical studies was 63-73.  A 
maximum score of 90 corresponded to good quality reporting and methodology.25 
With minimal regulatory oversight compared to the FDA regulations for drugs and 
devices, the lack of guidance and clear expectation may also contribute to lower rigor in surgical 
studies.  The FDA regulates development of new drugs and new devices.1, 3  New device 
approval for human use depends on a device’s Class designation.  Class I and Class II devices 
take a fast-track approval route that did not require a clinical trial for device approval before 
human use, because they are considered equivalent to prior approved devices.  Class III devices 
must demonstrate safety and effectiveness prior to approval.4  About 99% of new devices 
received approval via the fast-track route, but only 1% of all medical devices received approval 
for human use via premarketing clinical data.26  Although the use or implantation of devices is a 
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fundamental part of surgical procedures, the FDA does not regulate surgical innovation, and the 
DHHS does not have specific regulatory rules or evaluation criteria for surgical research.1,2,23   
Proposed reasons for the low number of RCTs in surgery are surgeons may be less 
tolerant of uncertainty about effectiveness of alternative treatment compared to other physicians, 
have insufficient methodological training in study design, and lack funding, support, and faculty 
development programs for surgical research.27  Potential reason for less tolerance of uncertainty 
and less initiative to conduct procedural RCTs among researchers are surgical interventions 
cannot be tested on cells and are difficult to test in other mammal models as a first pass in assess 
safety.  Surgical interventions are also not retractable, and there are no antidotes.  Explaining and 
justifying these risks of surgical innovation research to the IRB and the public, especially when 
there is no national regulatory approval process, are likely a more arduous undertaking for 
surgical researchers.   
Literature often highlights other ethical concerns of placebo studies, such as physicians 
actively deceiving patients, patients developing an allergic or adverse response to elements of the 
placebo, and patients possibly forgoing conventional treatments that are available and delaying 
treatment.2, 28, 29  Many of these ethical concerns seem unavoidable in both medical and surgical 
studies, but discussion of placebo controls in researcher attempts to define circumstances when 
study benefits may outweigh the risks and explain how to minimize these risks.  Primarily, 
studies are only necessary when there is clinical equipoise, when there is uncertainty and no 
preferred intervention for treating patients with a specific set of medical characteristics.30  This 
means studies that use placebo controls are investigating interventions for a specific group of 
patients where the current standard of care is not providing a therapeutic effect.  London and 
Kadane provided 5 claims to aid in evaluating the ethical appropriateness of a sham control 
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trial.31  Additionally, physician researchers can prevent deception by providing patients with 
appropriate information about the patient’s health, discussing the detail of the study, and 
obtaining informed consent for the study.30   
 
Blinding and Randomization in Surgical Research 
Blinding is particularly challenging in surgery studies.  A combination of surgeon-
selected or physician-centered (eg mortality and morbidity) and patient-centered (eg social and 
functional status) clinical outcomes need to be measured when assessing medical treatment 
efficacy and effectiveness.27  Patient-centered outcomes are often patient-reported and 
susceptible to the psychosocial context.  To account for the potentially therapeutic effects of the 
psychosocial context, studies use placebo control and blind patient’s to their intervention prior to 
outcome comparison and statistical analysis between groups.  In a surgery study, only a sham 
procedural control can recreate a comparable psychosocial context and make blinding of the 
patient possible.  Since surgeons operate on the patient, blinding of surgeons is not possible, but 
blinding of the clinician or data collector assessing outcomes is possible.27  Blinding non-
operative investigators and asking a standardized set of questions would prevent clinician 
measurement bias.  Blinding would also minimize the potential that the physician would treat, 
counsel, or converse with patients differently across study groups.  Inadequate blinding of 
patients can bias statistical analysis toward or away from detecting a significant difference in 
patient-reported outcomes, depending on the study control used.  Thus, a sham procedural 
control is helpful in preventing overestimation and underestimation of a procedure’s therapeutic 
effect on patient-reported outcomes (Figure 2). 
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Figure 1. Placebo Effect and Measuring Significant Difference  
 
People who expect and receive a more invasive treatment tend to report greater 
improvement or placebo effect compared to less invasive treatments.12  The magnitude of a 
placebo effect is associated with expectancy.6  Patients who experience greater expectancy tend 
to report a greater therapeutic effect.  The distance between a control and the intervention 
represent the difference in expectancy, which correlates with the magnitude of the difference in 
patient-reported outcomes.  Without blinding, there is potential for the larger placebo effect of a 
procedural intervention to be mistaken as a significant therapeutic difference when compared to 
a medicinal control that has a small placebo effect.  In contrast, the placebo effect of a procedural 
intervention compared to a procedural control is closer in magnitude, so comparison of 
therapeutic effect may result as an insignificant difference during analysis.  Without a sham 
procedural control, surgical studies analyzing patient-reported outcomes can be misleading. 
 
In addition to blinding, the complexity of creating an acceptable control and enrolling an 
adequate number of participants receptive to randomization in surgical studies is also 
challenging.  The primary purpose of randomization is to minimize confounding.  Even if 
patients adhere to their randomized treatment, large surgical research studies inherently possess 
additional confounders intrinsic to procedural interventions.  The variability in skills, 
preferences, and experience of the anesthesia team, medical team, nursing team, and the 
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surgeons involved in patient care are part of the intervention, which may be difficult to allocate 
randomly.  Furthermore, to create a “gold-standard” control of a surgical intervention, where a 
control patient receives a mirror experience of what a patient in the intervention group receives 
except that the treatment under investigation is not given, would require more medical staff per 
patient.  Given the size of the patient care team, blinding all those involved up to the point of 
surgery and after the point of surgery may be necessary to decrease measurement bias and 
equalize pre- and post-surgical patient-practitioner interactions.   
 
Standardizing the Process and Reporting of Surgical Innovation 
The growing cost of health care has increased the pressure for proven effective medical 
and surgical treatments.  As a greater volume of medical care involves treating slowly 
progressive diseases, it becomes more difficult to tell if a surgical intervention is effective.15  
Perhaps it is more difficult to distinguish or detect a true result from other confounding factors if 
a change in practice is subtle or the sought for outcomes are a long-term benefits rather than 
short-term improvements.  Ergina et al argue that when advances are more subtle, the need for 
RCTs is greater.27  When therapeutic outcomes are less apparent and detectable, well-designed 
randomized trials with sufficient initial investment of resources can lead to valid and reliable 
results faster.   
Innovation is a core component of surgical practice that follow a standardized model of 
development.  The American Society of University Surgeons describe surgeons as continuous 
innovators, because “surgeons are trained to perform continuous situational assessment, decision 
analysis, and improvisation, in preparation for the challenges and creativity required by nearly 
every clinical case.”  One could entertain the idea that because every encounter requires 
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innovation and innovation is a creative art, it would hinder surgical practice to place innovation 
within a formalized framework.  Others may think without a clear regulating body, there is 
concern for accepting small advances overoptimistically.32  In 2009, the Balliol Collaborative 
congregated to discuss how to advance and standardize surgical innovation and evaluation.  They 
recommend a reporting framework of five stages in surgical innovation to encourage the quality 
improvement of surgical study design and reporting.  They propose that published research 
should record and report surgeon experience, such that surgeons either receive specific training 
to participate in a study or complete an assessment of skill comparability and differences at the 
beginning of a study.  Another recommendation was to create specialty specific postoperative 
outcomes classifications modeled after the Clavien-Dindo classification of surgical 
complications.27  A graded classification establishes a common terminology, characterizes the 
degree of severity, and makes summarizing and comparing rates of clinical outcomes and 
complications easier.  The 2009 Lancet “Surgical Innovation and Evaluation” IDEAL paradigm 
series make the call to adapt and improve the quality of surgical studies.  The series did not 
explicitly encourage expanding the use of sham controls, but it acknowledges patient-reported 
outcomes are particularly susceptible to bias if participants are not masked.   
Thus, this pilot systematic review aims to investigate the use and reporting of sham 
procedural controls in cardiac surgery RCTs with patient-reported outcomes from 1/2005 to 
1/2016 in The Lancet and The New England Journal of Medicine.   
  
METHODS 
Cardiac RCTs published in The Lancet and The New England Journal of Medicine from 
1/2005 to 1/2016 were systematically reviewed to investigate the use and reporting of sham 
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procedural controls and to assess if there were changes in reporting to reflect the 2009 IDEAL 
framework for surgical innovation and evaluation.  These two journals were selected for their 
reputation of publishing influential peer-reviewed articles and wide readership, which implies 
studies of high quality are eligible for publication.  Given the rich history and wide variety of 
cardiac procedures, cardiology RCTs were the focus of this pilot systematic review.  
 
Study Identification 
 To identify randomized controlled trials in cardiology since 1/1/2005, the following 
search was conducting on PubMed: (cardiac[ti] OR heart[ti] OR coronary[ti] OR 
cardiovascular[ti] OR cardio*[ti] OR cardiol* OR mitral[ti] OR myocardial[ti] OR atrial[ti] OR 
aortic[ti]) AND (lancet[jour] OR nejm[jour]).  Additional databases were not used to identify 
articles, because the search was limited to publication in two prominent journals, The Lancet or 
The New England Journal of Medicine from 1/1/2005-3/11/16, which would be up to date on 
PubMed.  The PubMed searched for cardiology key words within abstracts to identify articles, 
because this method finds recently published articles that are awaiting MESH term coding. 
 
Study Selection 
Assessing Sham Procedural Control Relevance in Studies 
A sham procedural control creates a circumstance where both patients and the 
investigator measuring outcomes are unable to tell which groups a patient is randomized to.  The 
patient randomized to the sham group receives a procedure where a skin incision is made for the 
procedural intervention to be given, but ultimately, the therapeutic part of the intervention is not 
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given.  For this review, I identified studies that could have used a sham procedural control 
regardless of the control a study actually used (Table 1).   
 
Table 1. Deciding When Sham Procedure Controls are Relevant  
The purpose of a sham control is similar to that of a placebo medication.  That purpose is 
to blind both the patient and ideally the investigators collecting the data so that they do not know 
which study group the patient belongs to.  Blinding helps to minimize measurement bias, 
particularly when the outcome assessed is a patient-reported outcome, since individual 
perception and style of clinical questioning influences assessment of psychological states such as 
well-being and pain symptoms.   
 Intervention Control Placebo or Sham 
Relevant Control 
Example 
Medicinal Studies 
 M2 ---  placebo Antisense therapy to reduce 
apolipoprotein(a) synthesis33 
 M2 M1 ---blinding possible--- Bivalirudin vs heparin before 
PCI34 
 M2 + M1 M1                 M1 + placebo Nebivolol and/or valsartan for 
hypertension35 
Procedural Studies 
* P2 ---              Sham Endovascular aneurysm repair36 
 P2 P1 ---blinding possible--- Mitral valve repair vs. 
replacement37 
‡ P2 + P1 P1  P1 + Sham Mitral valve repair + Coronary 
artery bypass graft (CABG) vs. 
CABG38 
Mixed Medicinal and Procedural Studies 
 M2 + P1 P1 ---blinding possible--- Stent studies39 
 M2 + P1 P1 + M1 ---blinding possible--- Stent studies40 
‡ P2 + M1 M1                 M1+sham Coronary sinus reducing device 
in refractory angina41 
√ P2 M1 P2 + placebo 
M1 + sham 
Implantable cardioverter-
defibrillator vs. standard 
medical therapy42 
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M1 = Standard medical or management therapy, P1=Standard procedural therapy, M2 = 
medicine or management method under investigation, P2=procedural strategy under 
investigation. 
*Like placebo controls in drug studies, sham procedural controls are relevant when one is 
testing a new procedure against no known standard medication or procedure.  ‡Sham controls are 
also relevant when the procedural intervention studied is a complement to and deliverable in 
conjunction with a known standard medicinal or procedural therapy.  In many cases, there may 
be medications that are available, but the medications do not provide adequate treatment for a 
subgroup of patients.  √Lastly, a sham control is relevant when the study compares outcomes of a 
new procedure to a standard medical treatment, because giving a sham procedural placebo with 
the standard medical therapy and a placebo medication in place of the standard medication 
makes blinding possible.  
A sham procedure is neither relevant nor possible in new medication studies, but blinding 
may be possible with or without a placebo medication.  A sham is also not possible when 
studying two separate procedures that cannot be given as complementary therapy.  For example, 
a mitral valve repair compared to a mitral valve replacement.  It would be unethical to perform a 
sham surgery when a therapeutic procedure already exists.  Nevertheless, blinding of both the 
patients and investigator is possible.  Lastly, studies that investigate a change in medication —
whether administered before, during, or after the procedure —were classified as drug studies 
rather than procedural studies. 
 
Inclusion and Exclusion Criteria 
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 Randomized controlled trials of adults ≥ 18 years old were included if the study (1) 
investigated an intervention that involved an invasive procedure for treating a cardiac disease, (2) 
had the potential to use a sham control, whether it was actually used or not in the study (Table 1), 
and (3) assessed and reported patient-experienced and/or patient-reported outcomes (Table 2).   
Studies were excluded if (1) they were not a randomized controlled trail, (2) participants 
were < 18 years old, (2) the intervention was not an invasive procedure, (3) there was no single 
standard control, and (4) if the outcome was measured by a device and not a patient reported 
outcome (Table 2). 
 
Table 2. Inclusion and Exclusion Criteria  
Inclusion Exclusion (with examples) 
Randomized controlled trial Commentaries and letters 
Participants ≥ 18 years old Participants < 18 years old 
Intervention was: 
 an invasive procedure that treats 
cardiac disease 
 included a strategy to address 
unexpected surgical situations during 
the operation 
 
Intervention was: 
 A medicinal (oral, IV, infusion, stent 
coating) 
 Diet/lifestyle modification 
 An external equipment (CPR, CPAP, 
compression stocking) 
  Targeted lab or vital sign values 
(HbA1C, BP) 
 For diagnostic or management 
decisions (using FFR to determine 
operation given, timing of 
intervention) 
 Change in location of device 
implantation 
 Different use of implanted device 
(pacing, monitoring) 
 Organ transplant 
Control: 
 could have been a sham procedure 
 was a single standard control with a 
strategy to address unexpected 
Control is: 
 A procedure that is different from 
intervention (open vs. endovascular or 
repair vs. replace) 
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surgical situations during the 
operation 
 Not a single standard control, (control 
that includes standard medical therapy 
with or without another specified 
procedure) 
 A procedure given in conjunction with 
the intervention procedure  
Reported outcomes were patient-experienced 
and patient-reported 
Outcomes measured:  
 with a device (ambulatory BP) 
 unclear human or device measurement 
(home BP) 
 not patient-reported (mortality) 
 
The inclusion and exclusion criteria were determined in collaboration with Dr. Harris and 
Dr. Stouffer.  I independently reviewed all abstracts and full-texts for inclusion or exclusion.  
When there was uncertainty, Dr. Harris was asked to guide the decision making process by either 
direct review or explanatory clarification of inclusion and exclusion criteria.  I reviewed articles 
a maximum of 3-4 times before inclusion or exclusion was determined.  Abstract review focused 
on inclusion criteria (1) and (2), because some studies analyzed patient-reported outcomes as a 
secondary outcome not mentioned in the abstract.  Initial full-text review focused on screening 
for all inclusion criteria, before full-text reading for data extraction.     
 
Data Extraction 
 I extracted all the data from the full-text articles independently.  For each article, I 
extracted information about the purpose of the study, blinding of the patient and investigator, the 
patient population, the intervention and control used, amount of crossover between groups, type 
of patient-reported outcome measured, reported results, adverse events, and regulating bodies 
involved. 
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RESULTS 
Search Results 
 PubMed found 398 potential cardiology RCTs published in The Lancet and The New 
England Journal of Medicine.  Of the 11 articles that fit inclusion criteria, only 1 article was a 
true sham study (Figure 1). 
 
Figure 2. PRISMA diagram 
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Controls Used and Blinding 
Of the 11 studies that could have used a sham procedural control, only 1 was a double-
blinded sham RCT.  In the remaining 10 studies, patients were not blinded to their randomization 
group assignment.  Only 1 of the 10 studies explicitly stated blinding of the research assessor.  In 
that study, research assessors conducted patient-reported outcomes through phone interviews.  
The other 9 studies did not report on blinding of the research assessor (Table 3).  Both studies 
that blinded the research assessor were published after 2009.  Patient-reported outcomes were the 
primary outcome of interest in 4 of the 11 studies.   
 
Table 3. Controls used, Blinding, and Outcomes  
Article Intervention  Control  Blinding 
(intervention: 
control) 
Significant 
difference in 
patient 
reported 
outcomes 
between 
groups? 
36EVAR trial 
participants 
2005 
EVAR no intervention No : Unclear No 
43Hochman 
2006 
PCI with stent + 
control 
OMT No : Unclear   Yes  
44Oral 2006 CPVA + control amiodarone +2 
cardioversions 
No : Unclear Did not 
compare. 
42Mark 2008 shock only single 
lead/chamber ICD + 
SMT 
1) amiodarone placebo + 
SMT 
2) amiodarone + SMT 
No : Unclear Variable 
depending on 
measurement 
tool. 
45Weintraub 
2008 
PCI + control OMT No : Unclear Yes 
46Jones 2009 ventricular 
reconstruction + 
control 
CABG + medical therapy Unclear : 
Unclear 
No 
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47Kuck 2010 VT ablation followed 
by control 
defibrillator implantation  No : Unclear No 
48Cosedis 
Nielson 2012 
radiofrequency 
catheter ablation  
class 1C or 3 
antiarrhythmic drug 
No : Unclear Yes 
49Thiele 2013 IABP + control German/Austrian S3-
Guideline on cardiogenic 
shock including early 
revascularization + OMT 
No : Yes No 
38Smith 2014 MV repair + control CABG alone No : Unclear No 
41Verheye 
2015 
implantation of 
coronary-sins 
reducing device 
sham: similar for all of 
procedure except device 
was not placed 
Yes: Yes Yes 
CABG=coronary artery bypass graft, CPVA=circumferential pulmonary vein ablation, 
EVAR=endovascular aneurysm repair, IABP=intra-aortic balloon pump, ICD= implantable 
cardioverter-defibrillator, MV=mitral valve, OMT=optimal medical therapy, PCI=percutaneous 
coronary intervention, SMT=standard medical therapy, VT=ventricular tachycardia 
 
Assessing Significance in Patient-Reported Outcomes 
One study did not compare the patient reported outcomes between the study groups.  
When comparing patient reported outcomes between study groups, 4 of the 11 studies found a 
significant difference.  Of those, 3 compared a procedural intervention to a medical control and 1 
was a sham control.  No significant difference or mixed results in patient-reported outcomes 
were found in 6 of the 11 studies, but 4 of the studies used a control that included a procedure 
with or without medicine, 1 study used a medicine only control, and 1 study had no intervention 
as the control (Table 3). 
 
Reporting of Surgeon Experience, Adverse Events, and Regulatory Bodies 
No studies reported or commented surgeon experience.  7 of 11 articles reported adverse 
events, but reporting of adverse events and outcomes was not on a graded classification scale, 
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not even the validated Clavien-Dindo classification of surgical complication.  All 11 studies 
obtained institutional review board approval from the participating research center, but 7 
received additional approval and support from national organizations. 
 
DISCUSSION 
RCTs should always strive to blind the outcome assessor.  This means blinding the 
participant and the research assessor when the outcome is patient-reported, because both are 
providing a measure of the outcome.   In this pilot review, I identified 11 cardiac RCTs that 
could have used a sham procedural control to blind participants, but 10/11 did not use a sham 
control.  In 9 studies, participants were not blinded and blinding of the research assessor was not 
clearly stated.  The studies did not describe the process of collecting patient-reported outcomes.  
Blinding of research assessors may be unnecessary if the patient-reported outcomes were 
collected by asking patients complete a questionnaire.  One study only blinded the research 
assessor, who collected patient reported outcomes through a phone interview.  Given that 10/11 
studies did not blind the participants, the results for patient-reported outcomes in cardiac surgical 
studies are subject to high measurement bias.   
The studies did not explain why sham procedural controls were not used.  Studies may 
not have used sham procedural control, because it would have required the group of operating 
room staff to approximately double the participants they see, unless a study uses blocked 
randomization.  This would mean seeing 100-1,000 more patients for sham operations, which 
may have been an unnecessary investment of human and material resources as well as time in 
studies where the primary outcome of interest was a physician-centered outcome, such as 
mortality and mechanically measurable labs.  Patient-reported assessment was the secondary 
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outcome of interest in 7/11 of the studies reviewed.  In these cases, patient-reported outcome 
should be published with clear statements of limitations and implications or not be reported at 
all, because the high potential of measurement bias makes the results difficult to interpret and 
inapplicable.  As for the 3/11 studies and future surgical studies evaluating patient-reported 
outcomes as the primary outcome, sham procedural controls are recommended to minimize 
measurement bias and improve the validity and reliability of results.  Even if ethical concerns 
prevent a sham procedural control from being used, reports should better explain the reasoning 
for the control chosen, how the patient reported outcome was measured, such as by phone 
interview or mailed questionnaire, and the blinding status of research assessors.  Obstacles to 
including sham procedural controls in surgical studies may be due to challenges in obtaining IRB 
approval, risk of low study enrollment, cost, or fear of ethical dilemmas.  For example at UNC, 
only 1 sham study was submitted to the IRB from 1990-2016, but it was not approved.  These 
challenges are not unique to surgical studies.  Therefore, using sham procedural controls when 
relevant to the research question of interest is worth the appropriate initial investment.  Obtaining 
a precise, valid, and reliable answer during the initial investigation will prevent more people 
from having to enter future studies aimed to answer the same research question. 
Investigators can make use of sham procedures and double-blinding to account for the 
placebo effect.  Further, one can imagine that research may one-day result in a statistical 
calculation to account for placebo effect.   In “The Powerful Placebo” article, Beecher concluded 
on average the magnitude of the placebo effect was 35.2% from reviewing 15 placebo control 
trials.7, 50  Although this estimate did not represent all placebo types, it raises the question 
whether calculations can be performed to yield meaningful estimates of the magnitude of a 
placebo effect for study controls.  For example, the true sensitivity and specificity of a test 
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remains unknown, but studies help to give the most likely estimate of the true sensitivity and 
specificity, or present a range of the potential values.  If investigators can predictably account for 
the placebo effect during the analysis phase, this may prove useful for analyzing pilot studies 
before undertaking larger double-blinded sham procedural control studies.  However, this all 
remains speculative and is impossible at present, but sham controls are an applicable method for 
blinding and accounting for the placebo effect.   
A limitation of this study is that all abstract reviews, full-text reviews, and data extraction 
was completed by a single reviewer, but PRISMA recommends a double independent review.  
With a single review, there is the possibility articles that would have met the inclusion criteria 
may have been overlooked.  Limited evidence source is another concern, because article searches 
were limited to The Lancet and The New England Journal of Medicine.  It is possible that other 
journals may have different reporting standards for articles to be accepted for publication, but 
this does not change the finding that 10/11 of the surgery studies assessing quality of life 
outcomes for procedural interventions published in these two reputable journals were unreliable.     
 
CONCLUSION 
Surgical research that investigates the effect of a procedural intervention on patient-
reported outcomes often do not use a sham procedural control and do not provide sufficient 
reporting about methods of collecting the patient reported outcomes or the blinding status of the 
research assessor.  Future research should aim to use a sham control in surgical RCTs, where the 
primary outcome of interest is a patient reported outcome.  Surgical RCTs that evaluate patient 
reported outcomes as a secondary outcome of interest should refrain from assessing and 
reporting these secondary outcomes when the control is not a sham procedure.  The purpose of a 
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sham procedural control is to allow for participant and investigator blinding as a means of 
equalizing the psychosocial context experienced by participants—the placebo effect.  Besides a 
sham procedural control, there are no additional research methods to account for the placebo 
effect in surgical studies, unless there is a way to accurately account for it during data analysis.  
The challenges of using sham procedural controls may include obtaining IRB approval, risk of 
low study enrollment, cost, or fear of unavoidable ethical concerns, but they are not unique to 
surgical studies.  Therefore, surgical studies that plan to evaluate procedures using patient-
reported outcomes should strongly consider sham controls to improve study validity.  Publishers 
should refrain from publishing surgical RCTs that do not use sham controls when assessing 
patient-reported outcomes or at least request researchers to either clearly state limitations and 
implications of not using a sham procedural control or not include patient-report outcomes that 
are secondary outcomes of interest in the manuscript.   
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APPENDIX  
Appendix 1.  Full Evidence Table 
Table is organized by publication year. 
Acronyms: AAA=abdominal aortic aneurysm, BARIS= Bypass Angioplasty Revascularization Investigation Substudy on Economics 
and Quality of Life, CCS= Canadian Cardiovascular Society, CPVA=circumferential pulmonary vein ablation, DASI= Duke Activity 
Status Index, EQ VAS= EQ Visual Analogue Scale, EQ-5D= EuroQoL descriptive quality of life assessment in 5 dimensions, 
EVAR=Endovascular Aneurysm Repair, IABP: intra-aortic balloon pump, ICD=implantable cardioverter-defibrillator, LV=left 
ventricle, LVESI= Left ventricular reverse remodeling, NHLBI=National Heart, Lung, and Blood Institute, NYHA=New York Heart 
Association, OMT=optimal medical therapy, MLHF= Minnesota Living with Heart Failure Scale, PAD=peripheral artery disease, 
SAQ=Seattle Angina Questionnaire, SF-12= 12-item Short From Health Survey, SF-36= 36-item Short From Mental Health 
Inventory, SMT= state-of-the-art medical therapy, VT=ventricular tachycardia 
Article Purpose Patient population  
(location, inclusion and  
exclusion criteria) 
Study arms and 
Blinding 
(received/ 
randomized) 
Crossover 
(%) 
Patient Reported 
Outcome (primary 
or secondary, 
assessment method) 
Health Reported Outcome 
Results 
Adverse Events Regulating 
body 
36EVAR 
trial 
participants 
2005 
To examine if 
EVAR compared 
with no 
intervention would 
reduce the risk of 
aneurysm-related 
death from rupture 
and improve the 
long-term survival 
and health-related 
quality of life for 
patients with AAA 
≥5.5cm in diameter 
31/41 eligible hospitals. 
 
Inclusion: ≥60yo, 
AAA≥5.5cm diameter, unit 
for open repair. 
 
Exclusion: reported in 
previous publication. 
Intervention: 
146/166 
EVAR 
 
Control: 
125/172 
no intervention 
 
Blinding:  
No : Unclear 
 
 
 
20% did not 
adhere to 
allocated 
treatment. 
27% control to 
aneurysm 
exclusion, 
including 12 
cases of open 
repair.   
Secondary: SF36 
and EQ-5D 
 
Primary: all-cause 
mortality. 
SF36 and EQ-5D: EVAR vs 
control, physical component 
summary at 0-3mon compared to 
baseline -1.51 vs 0.48, p=0.04.  
Otherwise, no clear and consistent 
differences in QoL between the 2 
groups at any time.  
By 4 years, 43% 
of patients in 
EVAR group had 
at least 1 post-op 
complication 
compared to 18% 
in no 
intervention.  HR 
5.3 p<0.001.  
Considered 
whether the 
excess of 
respiratory deaths 
North-West 
Multicenter 
Research 
Ethics 
Committee 
(UK). 
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and unfit for open 
repair.  
 
 
in EVAR group 
was attributable 
to use of general 
anesthesia, but 
analysis showed 
no significance 
p=0.45. 
43Hochman 
2006 
To evaluate a 
strategy of routine 
PCI for total 
occlusion of the 
infarct-related 
artery 3-28 days 
after acute MI in 
reducing the 
occurrence of 
composite end 
point of death, 
reinfarction, or 
NYHA class 4 
heart failure. 
US, New Zealand, and 
Canada. 
 
Inclusion: total occlusion 
of infarct-related artery w/ 
poor or absent antegrade 
flow (TIMI≤1) on coronary 
angiography 3-28days after 
MI + EF<50% +/- proximal 
occlusion of major 
epicardial vessel with large 
risk region. 
 
Exclusion: NYHA class 3/4 
HF, shock, serum 
Cr>2.4mg/dL, 
angiographically sig Lt 
main or 3-vessel CAD, 
angina at rest, severe 
ischemia on stress testing. 
Intervention: 
1071/1082 
PCI with stent + 
control 
 
Control: 
---/1084 
OMT 
 
Blinding: 
No : Unclear   
3% control to 
PCI within 30 
days of 
randomization. 
6% control to 
PCI after 30 
days. 
0.4% control to 
CABG within 30 
days.  
Secondary: By 
phone, CCS and 
NYHA. 
 
Primary: death from 
any cause, nonfatal 
reinfection, and 
NYHA class 4 HF.  
CCS: at 4 mon and 1 year 
significantly fewer patients with 
angina in the PCI group.   
Declined over time in both groups. 
Difference between the 2 groups 
also declined over time.  No 
significant difference by 3 years.   
 
NYHA: at 4 years, no significant 
difference in NYHA class 3, 4, or 5 
HF. 
PCI group: death 
(0.2%), centrally 
adjudicated 
myocardial 
reinfarction 
(0.6%), NYHA 
class 4 HF 
(0.2%), cardiac 
tamponade 
(0.2%), stroke 
(0.1%) 
 
 
 
 
 
 
 
 
 
NHLBI and 
IRB at 
centers. 
44Oral 2006 To determine the 
long-term efficacy 
of CPVA in 
patients with 
chronic atrial 
fibrillation while 
taking into account 
the confounding 
variables of 
antiarrhythmic-
drug therapy and 
cardioversion 
1 hospital in Milan, 1 
hospital in Michigan. 
 
Inclusion: Atrial 
fibrillation >6mon without 
intervening spontaneous 
episodes of sinus rhythm 
and recurred within 1wk 
after cardioversion. 
 
Exclusion: age <18 or >70, 
Left atrial diameter >55mm, 
LVEJ<30%, 
contraindication to 
amiodarone therapy or 
warfarin, presence of 
mechanical prosthetic valve, 
history of CVA, presence of 
left atrial thrombus on 
transesophageal 
Intervention: 
77/77  
CPVA + control 
 
Control: 
69/69  
amiodarone +2 
cardioversions 
 
Blinding: 
No : Unclear 
 
77% control to 
intervention in 
whom recurrent 
atrial fibrillation 
developed more 
than 3mon after 
the 1st 
cardioversion. 
Secondary: Severity 
of arrhythmia 
symptoms.  
 
Primary: freedom 
from atrial fibrillation 
or flutter in the 
absence of 
antiarrhythmic-drug 
therapy.   
Arrhythmia symptoms: 
Patient in sinus rhythm had greater 
improvement in symptom severity 
score. 
Among patients in sinus rhythm, 
baseline=17 (SD 4), 12mon=6 (SD 
2) after CPVA. 
Among patients with recurrent atrial 
fibrillation, baseline= 17 (SD 4), 
12mon=12 (SD 4). 
Atypical flutters 
in CPVA group.  
1 intervention 
group, AV 
junction ablation 
and received 
pacemaker. 
1 66yo died of 
pneumonia 6mon 
after CPVA. 
2 had pacemaker 
placed or sick 
sinus syndrome 
unrelated to 
ablation or drug 
therapy. 
IRB at 
centers. 
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echocardiography, prior 
attempt at catheter or 
surgical ablation for atrial 
fibrillation 
42Mark 2008 To examine the 
effect of primary 
preventive ICD 
therapy on health-
related quality of 
life compared to 
amiodarone and 
placebo in the 
Sudden Cardiac 
Death in Heart 
Failure Trial 
(SCD-HeFT) 
US, Canada, and New 
Zealand.  
 
Inclusion: ≥18yo with 
NYHA class 3 or 4 due to 
ischemic or non-ischemic 
causes of LVEF ≤35%. 
 
Exclusion:  none reported 
Intervention: 
814/829 shock 
only single 
lead/chamber ICD 
+ SMT 
 
Control: 
829/847  
placebo + SMT. 
 
825/845  
amiodarone + 
SMT. 
 
Blinding:  
No : Unclear 
 
14% ICD people 
received open-
label amiodarone 
during some part 
of follow-up. 
188 (11%) drug 
to some form of 
ICD therapy, 
median time 
26.7mon. 
44 amiodarone 
to open label 
amiodarone. 
10% placebo to 
open label 
amiodarone. 
Primary: Structured 
interview. DASI, SF-
36, MLHF,  
time trade-off 
technique, rate 
health, total number 
of "bed days” and 
"disability days”,  
driving status, 
financial 
management status, 
and employed status 
with BARIS 
Unadjusted 
DASI: no significant difference 
between ICD vs placebo and 
amiodarone vs placebo at baseline, 
3, 12, 30months. 
 
SF-36: ICD vs placebo, baseline 76 
vs 76 p=0.17, 3months median 80 
vs 76 p=0.01, 12months median 80 
vs 76 p=0.003, 30month median 76 
vs 76 p=0.79. 
Amiodarone vs placebo, no 
statistical difference at follow up. 
 
Additional SF-36 scales: ICD vs 
placebo, significant difference at 
3months in all domain (physical 
function, emotional function, 
general health, social function, pain, 
vitality), significant difference at 
6month for emotional function, 
general health, social function, and 
pain index. 
Amiodarone vs placebo, 
significantly higher score on pain 
index at baseline, 3, 12, and 
30months. 
 
MLHF: ICD vs placebo, 
significantly better in ICD (median 
baseline 41 vs 43 p=0.77, 3mon 30 
vs 36 p=0.006, 12mon 32 vs 36 
p=0.07, 30mon 32 vs 36 p=0.05). 
Amiodarone vs placebo, no 
statistical difference. 
 
Time trade-off utility: ICD vs 
placebo, significant improvement in 
ICD at 3months median 75 vs 70 
p=0.002. 
 
Overall health rating: ICD vs 
placebo, significantly higher in ICD 
5% during 
implantation, 9% 
later in trail: 
clinical events 
requiring surgical 
correction, 
hospitalization, or 
new and 
otherwise 
unanticipated 
drug therapy. 
NHLBI and 
IRB at 
center. 
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group. 3months median 75 vs 70 
p=0.002, 12months median 75 vs 70 
p=0.05, 30months median 70 vs 70 
p=0.18. 
Comparing within ICD group, 
shock vs no shock:  
Shocked within 1month group had 
significant decrease in general 
health perception, role function 
physical, role function emotional, 
social function, and self-rated 
health.   
Shocked within 2months shocked 
showed similar pattern but 
diminished magnitude of 
differences.   
By 12months NO significant 
difference. 
 
"Bed days", "disability days", 
driving, manage finances, 
employment: no detectable effect 
by ICD therapy. 
Survival-adjusted analysis 
showed similar results 
45Weintraub 
2008 
To assess the effect 
of PCI on relief of 
angina and effect 
on health status on 
a broader level as 
part of the 
COURAGE trial, 
since primary 
outcome of 
COURAGE trial. 
50 centers in US and 
Canada. 
 
Inclusion:  stenosis 
of >70% in at least 1 major 
epicardial coronary artery 
with objective evidence of 
myocardial ischemia or 
stenosis ≥80% in at least 1 
coronary artery + classic 
angina without provocative 
testing. 
 
Exclusion: reported in 
previous publications  
Intervention: 
900s/1149 
PCI + control 
 
Control: 
900s/1138 
OMT 
 
Blinding: 
No : Unclear 
 
21% control to 
PCI within first 
3mon. 
Primary: SAQ and 
SF-36. 
SAQ:  
Best summary statement: "A greater 
proportion of the PCI group had 
clinically significant improvements 
in the scores for physical function, 
angina frequency, and quality of life 
for the first 6 months after 
randomization, but these differences 
were no longer significant by 12 
months."   
"There was an intermittent 
advantage of PCI w/ respect to the 
percentage of patients with 
clinically significant improvement 
in the lowest (most severe angina) 
and middle third for up to 2 years, 
depending on the domain." 
 
SF-36: improvement in all domains 
in both group up to 3 months.   
"The benefit across domains was 
less consistent than that seen in the 
 None reported Department 
of VA 
Cooperative 
Studies 
Program and 
IRB at 
centers. 
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results of the SAQ, with an 
advantage of PCI that was noted in 
most but not all domains and that 
had a shorter duration."   
At 6months, PCI group had greater 
clinically significant improvement 
in physical functioning and role 
limitations-physical.  No advantage 
at 12months. 
46Jones 2009 To test if surgical 
ventricular 
reconstruction, 
when added to 
CABG, would 
decrease the rate of 
death or 
hospitalization for 
a cardiac event, as 
compared with 
CABG alone.  
127 clinical sites in 26 
countries. 
 
Inclusion:  CAD amenable 
to CABG, LVEF≤35%. 
 
Exclusion: recent MI, need 
for aortic-valve 
replacement, planned PCI, 
or coexisting non-cardiac 
disease resulting in life 
expectancy <3yr. 
Intervention: 
454/501 
ventricular 
reconstruction + 
control 
 
Control: 
463/499  
CABG + medical 
therapy 
 
Blinding:  
Unclear : Unclear 
2% intervention 
to no surgery at 
all.   
7% intervention 
to CABG alone. 
2% CABG to no 
surgery.  
5% CABG to 
also ventricular 
reconstruction. 
 
Secondary: CCS and 
NYHA 
  
Primary: time to 
death from any cause 
or hospitalization for 
cardiac cause. 
CCS:  
Proportion with no angina increased 
and proportion with CCS class 3/4 
angina decreased.  CCS improved 
average of 1.7 classes, but no 
difference between groups p=0.48. 
 
NYHA:  class 1 heart failure (no 
symptom) increased and proportion 
with class 3/4 heart failure 
decreased.  NYHA improved 
average of 1 class in both cohorts, 
but no for difference between 
groups p=0.70. 
None reported Duke 
Clinical 
Research 
Institute and  
IRB at 
centers. 
47Kuck 2010 To assess 
prophylactic VT 
ablation followed 
by implantation of 
a cardioverter 
defibrillator in 
patients with 
previous MI, first 
episode of stable 
VT, and reduced 
LV function.   
16 participating European 
centers. 
 
Inclusions: 18-80yo, 
indication for ICD as 
secondary prevention after 
documented stable clinical 
VT without any reversible 
cause, CAD, previous MI, 
LEVF ≤50%. 
 
Exclusion: acute MI within 
preceding month, cardiac 
surgery within preceding 
2mon, protruding LV 
thrombus on echo before 
ablation, valvular heart 
disease, or a mechanical 
heart valve that precluded 
LV access, unstable angina, 
incessant ventricular 
tachycardia, bundle-branch 
re-entry tachycardia, 
contraindication to heparin, 
Intervention: 
52/54 
VT ablation 
followed by 
control 
 
Control: 
55/56  
defibrillator 
implantation 
 
Blinding:  
No : Unclear 
 
7% implant 
defibrillator 
before ablation, 
but these 
patients did not 
have any VT 
events before 
ablation. 
1 control 
received ICD 64 
days after 
randomization 
because of LV 
thrombus.   
Secondary: SF-36 
 
Primary: time from 
defibrillator 
implantation to 
recurrence of any 
sustained VT or VF. 
SF-36: at 12months, obtained 
assessed in 54/94 (57%) of patients.  
At 24 months obtained from 30/54 
(56%) patients.  Baseline-adjusted 
SF-36 mean scores were higher in 
ablation group in 6/8 scales after 
12mon and in 7/8 scores after 
24mon.  No significant different 
between groups.   
 None reported IRB at 
centers. 
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serum Cr>220, heart failure 
class 4, other medical 
condition likely to limit 
survival to <12mon.  
48Cosedis 
Nielson 
2012 
To compare long-
term efficacy of an 
initial strategy of 
radiofrequency 
catheter ablation 
with an initial 
strategy of 
antiarrhythmic 
drug therapy in a 
larger population 
of patients with 
paroxysmal atrial 
fibrillation. 
Denmark, Sweden, and 
Finland. 
 
Inclusion: symptomatic 
paroxysmal atrial 
fibrillation, candidate for 
rhythm-control therapy, ≥2 
episodes of symptomatic 
atrial fibrillation within 
preceding 6mon but no 
episode of atrial 
fibrillation >7days. 
 
Exclusion: >70yo, previous 
or ongoing treatment with 
class 1C or 3 antiarrhythmic 
drugs, contraindication to 
both class 1C and 3 agents, 
previous ablation for atrial 
fibrillation, left atrial 
diameter of >50mm, 
LVEF<40%, 
contraindication to oral 
anticoagulant, moderate-
severe MV disease, NYHA 
3 or4 at time of enrollment, 
expected surgery for 
structural heart disease, 
secondary atrial fibrillation. 
Intervention: 
140/146 
radiofrequency 
catheter ablation  
 
Control: 
146/148 class 1C 
or 3 
antiarrhythmic 
drug. 
If recurrent atrial 
fibrillation, then 
direct current 
cardioversion and 
other appropriate 
antiarrhythmic 
medication. 
If refractory, then 
offered ablation if 
appropriate. 
 
Blinding: 
No : Unclear 
 
9% ablation with 
antiarrhythmic 
drug at 24mon 
4% control to 
ablation. 
Secondary: 
SF-36, freedom from 
symptomatic atrial 
fibrillation, and 
cumulative and per-
visit burden of 
symptomatic atrial 
fibrillation.  
 
Primary: burden of 
atrial fibrillation on 
Holter monitor and 
cumulative burden of 
atrial fibrillation. 
 
SF36: physical and mental 
component improved overtime in 
both groups. 
Physical-component improved more 
over time in ablation group than 
drug group (44.3+/-8.9 baseline to 
50+/-8.8 24mon vs 45.2+/-8.9 
baseline to 47.9+/-8.9) p=0.001 
over time, p=0.01 interaction. 
 
Free from symptomatic atrial 
fibrillation: ablation vs drug, 93% 
vs 84%, p=0.01. 
 
Symptomatic atrial fibrillation: 
ablation vs drug, 95% v 84%, 
p=0.0006. 
Cumulative burden of symptomatic 
atrial fibrillation did not differ, 
p=0.12. 
 
 
20 in ablation, 3 
cardiac 
tamponade, 3 
died in study 
where 1 was 
procedure related 
cerebral stroke 
16 drug, 4 died in 
study. 
No significant 
difference 
between groups 
p=0.45. 
Danish Data 
Protection 
Agency and  
IRB at 
centers. 
49Thiele 
2013 
To assess long-
term clinical and 
quality of life 
outcomes of IABP 
support compared 
to control in acute 
MI with 
cardiogenic shock. 
37 German centers. 
 
Inclusion:  cardiogenic 
shock (systemic 
hypotension, pulmonary 
congestions, and signs of 
impaired organ perfusion) 
w/ planned early 
revascularization preferably 
by PCI. 
 
Exclusion: no intrinsic 
heart action, resuscitations 
for >30min, severe cerebral 
Intervention: 
288/301  
IABP + control 
 
Control: 
199/269 
German/Austrian 
S3-Guideline on 
cardiogenic shock 
including early 
revascularization + 
OMT 
 
Blinding: 
15% control to 
IABP, only 
allowed if 
patient 
developed a 
mechanical 
complication 
Primary: Structured 
phone interview. 
CCS, NYHA, EQ-
5D, EQ VAS 
NYHA class I or II:  
IABP vs control, at 12 months 
115/127 (91%) vs 118/126 (94%), 
p=0.36.  
 
CCS class I or II:  
IABP vs control, at 12 months 
125/127 (98%) vs 124/125 (99%, 
p=1.00. 
 
EQ-5D and EQ VAS: no 
significant difference between 
groups 
None reported National 
regulatory 
authorities 
and  
IRB at 
centers. 
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deficit, mechanical causes 
of cardiogenic shock, onset 
of shock>12hr, severe PAD 
precluding IABP insertion, 
aortic regurgitation>grade 2 
in severity, age >90yo, 
shock of other cause, other 
severe concomitant disease 
with life expectancy <6mon. 
No : Yes  
Summary: for survivors, self-
reported QoL was moderate to 
good.  There was no significant 
difference at 6 and 12months. 
38Smith 
2014 
To determine 
whether the 
potential benefits 
of mitral valve 
repair outweigh the 
increased risks of 
the procedure 
combined with 
CABG. 
26 centers in the 
Cardiothoracic Surgical 
Trials Network. 
 
Inclusion:  adults, 
multivessel CAD, moderate 
ischemic mitral 
regurgitation. 
 
Exclusion: not reported. 
Intervention: 
147/150 
MV repair + 
control 
 
Control: 
143/151  
CABG alone 
 
Blinding:  
No : Unclear 
2% CABG+MV 
to CABG alone, 
because 
surgeon's 
concern about 
risk associated 
with valve 
repair. 
5% CABG alone 
to CABG + MV, 
mostly by 
increase severity 
in mitral 
regurgitation on 
intraoperative 
TEE. 
Secondary: NYHA, 
MLHF, SF-12, and 
EQ-5D 
 
Primary: LVESVI. 
MLHF: median reduction from 
baseline in heart failure symptom 
combined procedure vs CABG only 
48.1% vs 44.8%. 
 
SF-12: physical subscale improved 
in combined procedure vs CABG 
only 14.3% vs 12.05%.  
 
Summary: No sig difference btw 
treatment groups with respect to any 
measurement of QoL or functional 
status amounting those surviving to 
12months. 
At 1year, 153 
events in CABG 
alone, 185 in 
combined 
p=0.15. 
Serious 
neurologic 
adverse events, 
including stroke, 
TIA, metabolic 
encephalopathy, 
was significantly 
higher in 
combined group 
p=0.03, as was 
rate of 
supraventricular 
arrhythmia 
p=0.03. 
Mean length of 
stay after surgery 
was shorter with 
CABG alone 9.4 
than with 
combined 11.3, 
p=0.002, as was 
mean length of 
stay in ICU 4.0 vs 
4.8 p=0.006. 
NIH and 
IRB at 
centers. 
41Verheye 
2015 
Phase 2 study. 
To examine 
whether the 
implantation of the 
coronary-sinus 
reducing device 
could effectively 
improve angina 
symptoms in 
11 clinical centers in Europe 
and Canada. 
 
Inclusion:  >18yo, had CCS 
class 3 or 4 angina despite 
OMT for 30 days prior to 
screening, limited treatment 
options for revascularization 
by CABG or PCI, evidence 
Intervention:  
52  
implantation of 
coronary-sins 
reducing device 
 
Control: 
52 
None Primary: CCS and 
SAQ  
CCS: intervention vs. sham,  
improvement of at least 2 CCS 
classes 35% vs 15% p=0.02; 
improvement of at least 1 CCS class 
71% vs 42% p=0.003. 
 
SAQ: intervention vs. sham, 
improved by 17.6 points vs 7.6 
points p=0.048, but no significant 
Serious 
periprocedural 
events in… 
Intervention 
group 
1 MI 
1 unstable angina 
1 Crohn’s disease 
flare. 
Relevant 
national 
authorities 
and  
IRB at 
centers. 
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patients with 
obstructive 
coronary artery 
disease who had 
concomitant 
evidence of 
reversible 
myocardial 
ischemia and who 
were not 
considered to be 
candidates for 
revascularization.  
of reversible ischemia that 
is attributable to left 
coronary arterial system, 
LVEF>25%, not pregnant.   
 
Exclusion: acute coronary 
syndrome <3mon ago, 
successful CABG or PCI 
<6mon ago, unstable angina 
<1mon ago, undergone 
placement of permanent 
pacemaker or defibrillator 
leads in the right heart. 
sham: similar for 
all of procedure 
except device was 
not placed 
 
Blinding:  
Yes: Yes 
difference between groups for 
angina stability or angina 
frequency.   
 
Sham group 
1 unstable angina 
1 epigastric pain. 
 
Total adverse 
events reported… 
76 in intervention 
group 
93 in sham group. 
 
Total serious 
adverse events in 
trial… 
10 in intervention 
group. 
24 in sham group. 
 
